CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for 4d Pharma PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

4d Pharma PLC
9 Bond Court
Phone: +44 1138950130p:+44 1138950130 LEEDS, LS1 2JZ  United Kingdom Fax: +44 1618376201f:+44 1618376201
Placed into Administration on 6/24/2022
On 6/24/2022, 4d Pharma PLC was placed into Administration. James Clark and David Pike of Interpath Advisory were appointed as the Administrators to 4d Pharma PLC. The Company's subsidiaries, 4D Pharma Research Limited, 4D Pharma Cork Limited, 4D Pharma León S.L.U. and 4D Pharma Delaware Incorporated, were not placed into Administration.
This company is no longer actively traded on any major stock exchange.
Business Summary
4D pharma plc is a United Kingdom-based pharmaceutical company. The Company is focused on developing Live Biotherapeutic Products (LBPs), a class of drugs derived from the human gut microbiome. The Company's LBPs are biologics based on live organisms, namely single strains of bacteria. It has developed MicroRx, its LBP discovery platform. MicroRx interrogates its library of bacterial isolates for therapeutic functionality and characterizes the bacterial isolates using a range of complementary tools and technologies. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) diseases. Its MicroRx enables the discovery of MRx-4DP0004, which is engaged in an ongoing Phase I/II with partly controlled asthma.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202112/31/2021Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board AxelGlasmacher 61 4/17/2020 1/7/2019
Chief Executive Officer, Executive Director Duncan J.Peyton 52 6/1/2014 6/1/2014
Chief Financial Officer JohnDoyle 1/4/2022 1/4/2022
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
4D Pharma Cork Ltd. C/O Quintas Heron House Blackpool Cork Ireland
4D Pharma Research Limited Life Science Innovation Building Aberdeen Scotland United Kingdom

Business Names
Business Name
4D Pharma (BVI) Limited
4D Pharma Cork Limited
4D Pharma Delaware Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 95 (As of 12/31/2021)
Outstanding Shares: 180,337,577 (As of 6/8/2022)
Stock Exchange: LON
Fax Number: +44 1618376201


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 2, 2024